UBS AG Analysts Give Novartis AG (NOVN) a CHF 78 Price Target

UBS AG set a CHF 78 target price on Novartis AG (VTX:NOVN) in a research note issued to investors on Monday morning, www.boersen-zeitung.de reports. The brokerage currently has a neutral rating on the stock.

A number of other analysts have also issued reports on the stock. Goldman Sachs Group, Inc. (The) set a CHF 80 price target on shares of Novartis AG and gave the stock a neutral rating in a research note on Tuesday, October 17th. Morgan Stanley set a CHF 88 price target on shares of Novartis AG and gave the stock a buy rating in a research note on Wednesday, July 26th. Berenberg Bank set a CHF 85 price target on shares of Novartis AG and gave the stock a neutral rating in a research note on Friday, July 14th. Deutsche Bank AG set a CHF 80 price target on shares of Novartis AG and gave the stock a neutral rating in a research note on Friday, July 7th. Finally, Sanford C. Bernstein set a CHF 94 price target on shares of Novartis AG and gave the stock a buy rating in a research note on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of CHF 86.10.

ILLEGAL ACTIVITY WARNING: “UBS AG Analysts Give Novartis AG (NOVN) a CHF 78 Price Target” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/03/ubs-ag-analysts-give-novartis-ag-novn-a-chf-78-price-target.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit